Lucid Diagnostics, Inc. (LUCD)
0.4077
+0.01
(+2.18%)
USD |
NASDAQ |
Nov 18, 16:00
0.399
-0.01
(-2.13%)
After-Hours: 20:00
Lucid Diagnostics Shareholders Equity (Quarterly) : 5.932M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 5.932M |
| June 30, 2026 | 10.93M |
| March 31, 2026 | 4.00M |
| December 31, 2025 | 10.94M |
| September 30, 2025 | 25.84M |
| June 30, 2025 | 7.862M |
| March 31, 2025 | -5.377M |
| December 31, 2024 | 5.391M |
| September 30, 2024 | 6.338M |
| June 30, 2024 | 15.98M |
| March 31, 2024 | 11.89M |
| December 31, 2023 | -2.311M |
| September 30, 2023 | 2.556M |
| June 30, 2023 | 15.07M |
| March 31, 2023 | 24.91M |
| December 31, 2022 | 23.05M |
| Date | Value |
|---|---|
| September 30, 2022 | 27.53M |
| June 30, 2022 | 36.24M |
| March 31, 2022 | 46.49M |
| December 31, 2021 | 54.74M |
| September 30, 2021 | -24.13M |
| June 30, 2021 | -19.95M |
| March 31, 2021 | -16.37M |
| December 31, 2020 | -13.52M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -5.309M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -1.063M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| PAVmed, Inc. | 27.46M |
| Stereotaxis, Inc. | 26.53M |
| Glaukos Corp. | 717.27M |
| CVRx, Inc. | 13.82M |
| Hyperfine, Inc. | 31.74M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 27.86M |
| Total Liabilities (Quarterly) | 21.92M |
| Debt to Equity Ratio | 3.116 |
| Current Ratio | 1.200 |
| Net Debt Paydown Yield | 1.26% |